The Relative Strength (RS) Rating for Jazz Pharmaceuticals entered a new percentile Tuesday, with a rise from 79 to 82.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
History reveals that the best stocks typically have an RS Rating of above 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While the stock is not near an ideal buying range right now, see if it goes on to form and break out of a proper chart pattern.
Jazz Pharmaceuticals posted 31% EPS growth last quarter. Revenue increased 8%. The next quarterly numbers are expected on or around Apr. 30.
The company holds the No. 5 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
